Fast Market Research

Colorectal Cancer - Pipeline Review, H2 2016 - New Market Study Published

Fast Market Research announces the availability of the new Global Markets Direct report, "Colorectal Cancer - Pipeline Review, H2 2016", on their comprehensive research portal


Boston, MA -- (SBWIRE) -- 02/13/2017 -- Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Colorectal Cancer - Pipeline Review, H2 2016, provides an overview of the Colorectal Cancer (Oncology) pipeline landscape.

Colon cancer is cancer that starts in the large intestine (colon). There is no single cause of colon cancer. Nearly all colon cancers begin as noncancerous (benign) polyps, which slowly develop into cancer. Many cases of colon cancer have no symptoms. The following symptoms may indicate colon cancer abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, or other change in bowel habits, narrow stools and weight loss with no known reason. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Colorectal Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Colorectal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Get More Details on this Report and a Full Table of Contents at Colorectal Cancer - Pipeline Review, H2 2016

The Colorectal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Colorectal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 26, 106, 110, 9, 145, 36 and 9 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 15, 8, 22 and 3 molecules, respectively.

Colorectal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Report Scope

-The pipeline guide provides a snapshot of the global therapeutic landscape of Colorectal Cancer (Oncology).

-The pipeline guide reviews pipeline therapeutics for Colorectal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

-The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

-The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

-The pipeline guide reviews key companies involved in Colorectal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

-The pipeline guide evaluates Colorectal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

-The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

-The pipeline guide reviews latest news related to pipeline therapeutics for Colorectal Cancer (Oncology)

Reasons to Get this Report

-Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

-Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

-Find and recognize significant and varied types of therapeutics under development for Colorectal Cancer (Oncology).

-Classify potential new clients or partners in the target demographic.

-Develop tactical initiatives by understanding the focus areas of leading companies.

-Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

-Formulate corrective measures for pipeline projects by understanding Colorectal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Companies Mentioned in this Report: 2cureX ApS, 3-V Biosciences Inc, 3M Drug Delivery Systems, 3SBio Inc, 4SC AG, AB Science SA, AbbVie Inc, AbGenomics International Inc, Accelerated Pharma Inc, Adamed Sp z oo, Aduro BioTech Inc, Advenchen Laboratories LLC, Alchemia Ltd, Allinky Biopharma, Amal Therapeutics SA, amcure GmbH, Amgen Inc, Antibe Therapeutics Inc, Apac Biotech Pvt Ltd, Apexigen Inc, Aphios Corp, Aposense Ltd, Arisaph Pharmaceuticals Inc, ARMO Biosciences Inc, ArQule Inc, Array BioPharma Inc, Asana BioSciences LLC, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, Astex Pharmaceuticals Inc, AstraZeneca Plc, ATLAB Pharma SAS, AVEO Pharmaceuticals Inc, B Cell Design SAS, Basilea Pharmaceutica Ltd, Bavarian Nordic A/S, Bayer AG, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Biocon Ltd, Bionomics Ltd, Bionovis SA, Biotecnol Ltd, Biothera Pharmaceutical Inc, Boehringer Ingelheim GmbH, Boston Biomedical Inc, Bristol-Myers Squibb Company, Burzynski Research Institute Inc, Calithera Biosciences Inc, Cancer Prevention Pharmaceuticals Inc, Carna Biosciences Inc, Cascadian Therapeutics Inc, CBT Pharmaceuticals Inc, CCRP Therapeutics GmbH, Celgene Corp, Cellceutix Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celltrion Inc, Celyad SA, Chiome Bioscience Inc, Chipscreen Biosciences Ltd, ChoDang Pharm Co Ltd, Cipla Ltd, Cleave Biosciences Inc, Cleveland BioLabs Inc, COARE Biotechnology Inc, Coherus BioSciences Inc, Compugen Ltd, Cornerstone Pharmaceuticals Inc, Corvus Pharmaceuticals Inc, Critical Outcome Technologies Inc, CrystalGenomics Inc, Cytune Pharma SAS, Daiichi Sankyo Company Ltd, DanDrit Biotech A/S, Deciphera Pharmaceuticals LLC, Dicerna Pharmaceuticals Inc, Double Bond Pharmaceutical International AB, Dr. Reddy's Laboratories Ltd, EirGenix Inc, Eisai Co Ltd, Eli Lilly and Company, Endor Nanotechnologies SL, enGene Inc, EnGeneIC Ltd, Ensol Biosciences Inc, EntreChem SL, Enzo Biochem Inc, Etubics Corp, Exelixis Inc, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Formosa Laboratories Inc, Fusion Antibodies Ltd, Gene Techno Science Co Ltd, Genentech Inc, Genor BioPharma Co Ltd, Genoscience Pharma, Genzyme Corp, Gilead Sciences Inc, GlaxoSmithKline Plc, Glycotope GmbH, Golden Biotechnology Corp, Green Cross Corp, Hadasit Medical Research Services & Development Ltd, Handok Inc, Hanmi Pharmaceuticals Co Ltd, Heat Biologics Inc, Hemispherx Biopharma Inc, Hutchison MediPharma Ltd, iDD biotech SAS, Ideaya Biosciences Inc, Ignyta Inc, Immodulon Therapeutics Ltd, ImmuneXcite Inc, Immunomedics Inc, Immunovative Therapies Ltd, Incanthera Ltd, Incyte Corp, Innovent Biologics Inc, Inovio Pharmaceuticals Inc, Interprotein Corp, Intezyne Technologies Inc, Ionis Pharmaceuticals Inc, IPD Therapeutics BV, Isofol Medical AB, Jeil Pharmaceutical Co Ltd, JHL Biotech Inc, Jiangsu Hengrui Medicine Co Ltd, Johnson & Johnson, KaloBios Pharmaceuticals Inc, Kancera AB, Karyopharm Therapeutics Inc, Kura Oncology Inc, Laboratorio ELEA SACIF y A, Lee's Pharmaceutical Holdings Ltd, Lion Biotechnologies Inc, LipoMedix Pharmaceutical Inc, Loxo Oncology, Inc., Mabion SA, Mabtech Ltd, mAbxience SA, MacroGenics Inc, Marina Biotech Inc, MediaPharma srl, MedImmune LLC, Medinet Co Ltd, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Merus NV, Microlin Bio, Inc., MolMed SpA, Mologen AG, Morphotek Inc, Multimmune GmbH, Mycenax Biotech Inc, Natco Pharma Ltd, NatureWise Biotech & Medicals Corp, Nektar Therapeutics, Neovacs SA, Nerviano Medical Sciences Srl, Nippon Kayaku Co Ltd, NormOxys Inc, Northwest Biotherapeutics Inc, Novartis AG, Novogen Ltd, Noxxon Pharma AG, NuCana BioMed Ltd, OBI Pharma Inc, Oncobiologics Inc, Oncolytics Biotech Inc, OncoMed Pharmaceuticals Inc, Onconova Therapeutics Inc, Ono Pharmaceutical Co Ltd, Oryx GmbH & Co KG, Otsuka Holdings Co Ltd, Oxford BioMedica Plc, Pfizer Inc, Pharma Mar SA, PharmAbcine Inc, Pivot Pharmaceuticals Inc, Pivotal BioSciences Inc, PlantForm Corp, PLx Pharma Inc, Precision Biologics Inc, Prima BioMed Ltd, Propanc Health Group Corp, Provectus Biopharmaceuticals Inc, PsiOxus Therapeutics Ltd, Puma Biotechnology Inc, R Pharm, RedHill Biopharma Ltd, Redx Pharma Plc, Regeneron Pharmaceuticals Inc, Rexahn Pharmaceuticals Inc, Rgenix Inc, Rhizen Pharmaceuticals SA, Richter Gedeon Nyrt, Samumed LLC, Sanofi, Selvita SA, Shanghai Henlius Biotech Co Ltd, Shire Plc, Sigma-Tau SpA, Sigmoid Pharma Ltd, Sillajen Biotherapeutics, Solvotrin Therapeutics Ltd, Sorrento Therapeutics Inc, Sumitomo Dainippon Pharma Co Ltd, SuviCa Inc, Symphogen A/S, Synermore Biologics Co Ltd, Taiho Pharmaceutical Co Ltd, TaiwanJ Pharmaceuticals Co Ltd, Takeda Pharmaceutical Company Ltd, Tara Immuno-Oncology Therapeutics LLC, Targovax ASA, Tarveda Therapeutics Inc, Theravectys SA, Tiltan Pharma Ltd, Tocagen Inc, TRACON Pharmaceuticals Inc, Transgene SA, TyrNovo Ltd, United BioPharma Inc, Vaccinex Inc, VasGene Therapeutics Inc, Vaximm AG, Verastem Inc, Vertex Pharmaceuticals Inc, Viralytics Ltd, Wilex AG, WntResearch AB, XBiotech Inc, XuanZhu Pharma Co Ltd, Zymeworks Inc

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Drug Pipeline research reports at Fast Market Research

You may also be interested in these related reports:
-Metastatic Colorectal Cancer - Pipeline Review, H2 2016
-Esophageal Cancer - Pipeline Review, H2 2016
-Esophageal Cancer - Pipeline Review, H2 2016
-Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H2 2016
-Head And Neck Cancer - Pipeline Review, H2 2016